Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mupadolimab - Corvus Pharmaceuticals

Next Previous
X
Search
Drug Profile

Mupadolimab - Corvus Pharmaceuticals

Alternative Names: Adenosine production inhibitor - Corvus Pharmaceuticals; Anti-CD-73 monoclonal antibody-Corvus Pharmaceuticals; COR-004 - Corvus Pharmaceuticals; CPI-006; CPX-006

Latest Information Update: 17 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corvus Pharmaceuticals
  • Developer Angel Pharmaceuticals; Corvus Pharmaceuticals
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Head and neck cancer; Non-small cell lung cancer; Oropharyngeal cancer
  • Phase I Cancer
  • Discontinued COVID 2019 infections

Most Recent Events

  • 06 May 2024 Corvus Pharmaceuticals initiates phase-I clinical trials in Head and neck cancer (Monotherapy, Combination therapy, Late-stage disease) in China (IV)
  • 06 May 2024 Corvus Pharmaceuticals initiates phase-I clinical trials in Non-small cell lung cancer (Monotherapy, Combination therapy, Late-stage disease) in China (IV)
  • 05 Jan 2024 Corvus Pharmaceuticals completes a phase I trial in Cancer (Late-stage disease, Monotherapy, Second-line therapy or greater) in the USA and Australia (IV) (NCT03454451)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top